Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML)

被引：0
|
作者：
Garcia-Manero, G.
Yang, A. S.
Klimek, V.
Luger, S.
Newsome, W. M.
Berman, N.
Patterson, T.
Maroun, C.
Li, Z.
Ward, R.
Martell, R.
机构：
[1] UT MD Anderson Canc Ctr, Houston, TX USA
[2] Norris Cromprenhens Canc Ctr, Los Angeles, CA USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA
[5] MethylGene, Montreal, PQ, Canada
[6] Pharmion, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7062
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Phase I study of an oral isotype-selective histone deacetylase (HDAC) inhibitor in patients (pts) with advanced solid tumors
    Siu, L. L.
    Carducci, M.
    Chen, E. X.
    Maclean, M.
    Pili, R.
    King, S.
    Patterson, T.
    Li, Z.
    Kalita, A.
    Reid, G. K.
    EJC SUPPLEMENTS, 2006, 4 (12): : 94 - 95
  • [12] Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study
    Younes, A.
    Andreadis, C.
    Assouline, S.
    Rizzieri, D.
    Wedwood, A.
    McLaughlin, P.
    Laille, E.
    Li, Z.
    Martell, R. E.
    Crump, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 162 - 162
  • [13] A phase I study of the histone deacetylase inhibitor MGCD0103 (MG-0103) given as a three-times weekly oral dose in patients with leukemia or myelodysplastic syndromes (MDS).
    Garcia-Manero, G
    Minden, M
    Estrov, Z
    Verstovsek, S
    Fiorentino, J
    Kantarjian, H
    Reid, G
    Martell, RE
    BLOOD, 2005, 106 (11) : 239B - 239B
  • [14] Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study
    Crump, M.
    Andreadis, C.
    Assouline, S.
    Rizzieri, D.
    Wedgwood, A.
    McLaughlin, P.
    Laille, E.
    Li, Z.
    Martell, R. E.
    Younes, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [15] Mocetinostat (MGCD0103), An Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, Produces Clinical Responses In Relapsed/Refractory Hodgkin Lymphoma (HL): Update From a Phase II Clinical Study
    Younes, Anas
    Bociek, R. Gregory
    Kuruvilla, John
    Laneuville, Pierre
    Fung, Henry C.
    Drouin, Michel
    Patterson, Tracy
    Besterman, Jeffrey
    Martell, Robert E.
    BLOOD, 2010, 116 (21) : 735 - 735
  • [16] Pharmacodynamic effect of MGCD0103, an oral isotype-selective histone deacetylase (HDAC) inhibitor, on HDAC enzyme inhibition and histone acetylation induction in phase I clinical trials in patients (pts) with advanced solid tumors or non-Hodgkin's lymphoma (NHL)
    Kalita, A
    Maroun, C
    Bonfils, C
    Gelmon, K
    Siu, LL
    Tolcher, A
    Carducci, M
    Besterman, JM
    Reid, GK
    Li, Z
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 869S - 869S
  • [17] A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma
    Younes, A.
    Fanale, M.
    Pro, B.
    McLaughlin, P.
    Neelapu, S.
    Fayad, L.
    Wedgwood, A.
    Dubay, M.
    Backstrom, J.
    Martell, R. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [18] A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Wilhelm, Francois
    Hearn, Katherine
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney D.
    Konopleva, Marina
    Borthakur, Gautam
    Azarnia, Nozar
    Silverman, Lewis R.
    BLOOD, 2014, 124 (21)
  • [19] A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: A New York Cancer Consortium
    Silverman, L. R.
    Verma, A.
    Odchimar-Reissig, R.
    Cozza, A.
    Najfeld, V.
    Licht, J. D.
    Zwiebel, J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [20] Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
    Daver, Naval Guastad
    Kantarjian, Hagop M.
    Pierce, Sherry
    Brandt, Mark
    Dinardo, Courtney Denton
    Pemmaraju, Naveen
    Vaughan, Kenneth
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Borthakur, Gautam
    Kadia, Tapan M.
    Cortes, Jorge E.
    Craig, Adam
    Ravandi, Farhad
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345